Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

KHEDEZLA

DESVENLAFAXINE

Standard Dose
100MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview KHEDEZLA is listed in Drugs@FDA under application 204683 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DESVENLAFAXINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 100MG Sponsor OSMOTICA PHARM CORP Submission history Latest submission status date: 2021-09-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview KHEDEZLA is listed in Drugs@FDA under application 204683 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DESVENLAFAXINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 100MG Sponsor OSMOTICA PHARM CORP Submission history Latest submission status date: 2021-09-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.